Swiss National Bank Sells 67,000 Shares of Zoetis Inc. $ZTS

Swiss National Bank lessened its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 1,283,332 shares of the company’s stock after selling 67,000 shares during the period. Swiss National Bank’s holdings in Zoetis were worth $187,777,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ZTS. CIBC Asset Management Inc raised its position in shares of Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after acquiring an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after purchasing an additional 18,040 shares during the period. Ninety One UK Ltd boosted its position in shares of Zoetis by 19.6% during the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after purchasing an additional 183,686 shares in the last quarter. Quilter Plc boosted its position in shares of Zoetis by 10.2% during the 3rd quarter. Quilter Plc now owns 438,959 shares of the company’s stock valued at $64,228,000 after purchasing an additional 40,615 shares in the last quarter. Finally, Swedbank AB grew its stake in Zoetis by 60.4% during the third quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after purchasing an additional 917,598 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $122.29 on Tuesday. The firm has a market capitalization of $51.62 billion, a P/E ratio of 20.31, a P/E/G ratio of 1.85 and a beta of 0.95. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00. The stock has a 50 day moving average price of $125.99 and a two-hundred day moving average price of $132.65. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several recent analyst reports. KeyCorp assumed coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. Bank of America increased their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Finally, HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.